KLRG1 and neoplasm: In a separate patient, we confirmed enhancement of tumor killing by circulating and intratumoral CD4+ T cells by E-cadherin blockade that is specific for KLRG1, and also MHC class II in agreement with our prior findings (7), and was not impacted by isotype control antibodies (Supplemental Figure 7C).